Full Press Release Details
Abivax to Participate in Upcoming Fall Investor Conferences
PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced participation in the following upcoming fall investor conferences:
Guggenheim Healthcare Innovation Conference Boston, Massachusetts November 9-11, 2026 Fireside Chat: Tuesday, November 10th, 10:30-10:55am ET
LifeSci Capital X Sofinnova Growth & Innovation Summit London, United Kingdom November 16, 2026
30th German Equity Forum (Deutsches Eigenkapitalforum) Frankfurt, Germany November 23-25, 2026 Corporate Presentation: Monday, November 23rd, 11:40am-12:10pm CET
Evercore ISI 9th Annual Healthcare Conference Miami, Florida November 30 – December 2, 2026 Fireside Chat: Wednesday, December 2nd, 7:55-8:15am ET
Piper Sandler 38th Annual Healthcare Conference New York, New York December 1-3, 2026 Fireside Chat: Thursday, December 3rd, 8:00-8:25am ET
Webcast links for select presentations will be available in the Investors section of Abivax’s website at www.ir.abivax.com. A replay of the available webcasts will also be available on the Company’s website for a limited time following the conference.
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Contact:
Abivax SA Patrick Malloy SVP, Investor Relations patrick.malloy@abivax.com +1 847 987 4878